Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network.

Publication Type:

Journal Article


Lung cancer (Amsterdam, Netherlands), Volume 78, Issue 3, p.245-52 (2012)


2012, Center-Authored Paper, Clinical Research Division, October 2012


Relatively low rates of chemotherapy receipt have been observed in older patients diagnosed with advanced non-small cell lung cancer (NSCLC) in SEER-Medicare-based studies. However, little is known about variation in first-line NSCLC chemotherapy use in younger patients, health maintenance organization (HMO)-based settings, and for high-cost, novel agents, such as bevacizumab and erlotinib.